2017

LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,400,000 American Depositary Shares (“ADSs”), representing 28,800,000 ordinary […]

by

LONDON, Dec. 11, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 2,400,000 American Depositary Shares […]

by

LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares […]

by

COSTA MESA, CA–(Marketwired – Nov 6, 2017) – NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that data obtained from the company’s research and development partner, the University of Mississippi (UM), will be presented at upcoming scientific meetings in November. Research under the direction of Dr. Kenneth Sufka (University of Mississippi) utilizing cannabinoid research led by Dr. […]

by

MMJ BioScience’s FDA application to initiate clinical trials assessing the company’s cannabinoid pharmaceutical compounds for treating and/or preventing symptoms associated with multiple sclerosis (MS) has been filed Buffalo, New York December 09, 2017 MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and […]

by

MMJ BioScience’s FDA application to initiate clinical trials assessing the company’s cannabinoid pharmaceutical compounds for treating and/or preventing symptoms associated with multiple sclerosis (MS) has been filed Buffalo, New York (PRWEB) December 09, 2017 MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research […]

by

While many cannabis cultivators utilize biological insects throughout their integrated pest management (IPM) programs, they also turn to biological pesticides and fungicides to combat and prevent outbreaks in their cultivation facilities. (In Colorado alone, there are just under 300 approved pesticides and fungicides available to cultivators for legal use within their growing operations, documents on […]

by

LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,400,000 American Depositary Shares (“ADSs”), representing 28,800,000 ordinary […]

by

NORML | December 7, 2017 TEL AVIV, ISRAEL — The oral administration of gelatin capsules containing purified cannabidiol (CBD) is safe and efficient in human subjects, according to clinical trial data published online ahead of print in the journal Clinical Pharmacology in Drug Development. Israeli investigators evaluated the safety and tolerability of 10mg and 100mg oral doses of CBD […]

by

NORML | December 7, 2017 TEL AVIV, ISRAEL — The oral administration of gelatin capsules containing purified cannabidiol (CBD) is safe and efficient in human subjects, according to clinical trial data published online ahead of print in the journal Clinical Pharmacology in Drug Development. Israeli investigators evaluated the safety and tolerability of 10mg and 100mg oral doses of CBD […]

by

British company GW Pharma will sell more than 2 million shares on NASDAQ, which will bring in the money needed to advance its impressive pipeline even further. GW Pharma focuses on the development of therapeutics using its cannabinoid product platform for a range of diseases, including autism, epilepsy and brain cancer. Today, the company announced the […]

by

Tel Aviv, Israel: The oral administration of gelatin capsules containing purified cannabidiol (CBD) is safe and efficient in human subjects, according to clinical trial data published online ahead of print in the journal Clinical Pharmacology in Drug Development. Israeli investigators evaluated the safety and tolerability of 10mg and 100mg oral doses of CBD encapsulated in a proprietary gelatin mold. […]

by

Admittedly, 2017 so far has kind of been a ho-hum year for former high-flying marijuana stock GW Pharmaceuticals (NASDAQ:GWPH). For the most part, investors have just been waiting for the next big event for the cannabinoid-focused biotech. GW Pharmaceuticals CEO Justin Gover doesn’t think they’ll have to wait much longer. Speaking at the Piper Jaffray […]

by

LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares […]

by